The US Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a first-in-class non-opioid painkiller, to treat moderate to severe acute pain in adults. Manufactured by Vertex Pharmaceuticals, Journavx works by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain.
This innovative treatment offers a new alternative to traditional opioid painkillers, which have been linked to addiction and overdose risks. The FDA’s approval marks a significant step forward for patients seeking effective pain management without relying on opioids.
Source: https://www.aha.org/news/headline/2025-01-31-fda-approves-first-class-non-opioid-painkiller